ISRCTN82040078 https://doi.org/10.1186/ISRCTN82040078

Do Xanthine Oxidase Inhibitors (XOI) have clinically useful anti-ischaemic effects in the treatment of angina pectoris? A double-blind, placebo controlled trial

Submission date
22/06/2007

Registration date
26/06/2007

Last Edited
15/06/2010

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Circulatory System

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Awsan Noman

Contact details
Department of Clinical Pharmacology (Level 7)
Ninewells Hospital and Medical School
Dundee
United Kingdom
DD1 9SY

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NOM001

Study information

Scientific Title

Study objectives
Investigating if allopurinol (a Xanthine Oxidase Inhibitor [XOI]) has anti-ischaemic effects in the treatment of chronic stable angina patients.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved by Tayside Committee on Medical Ethics in November 2006 (ref: 06/S1401/133).

Study design
Double blind, placebo controlled, crossover trial.

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Coronary Artery Disease - patients with chronic stable angina

Interventions
Drug: allopurinol 300 mg - 600 mg given for six weeks.

Allopurinol (the intervention drug) is given orally (p.o.). Starting dose is 100 mg once daily (od). This is escalated over two weeks to a maximum dose of 300 mg twice daily (bd), which is given for a further period of four weeks (total six weeks). With regards to the control group, this trial is of a crossover design so each patient will be his/her own control. The placebo will be given in exactly the same fashion as the allopurinol for a total period of six weeks.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Allopurinol (a Xanthine Oxidase Inhibitor [XOI])

Primary outcome measure
Time to ST depression on ETT.

Outcomes will be assessed at the start and every six weeks (at the end of each treatment period - allopurinol or placebo).

Secondary outcome measures
1. Total exercise time
2. Time to symptom on ETT
3. Assessment of angina
4. Measurement of C-Reactive Protein (CRP), B-type Natriuretic Peptide (BNP) and Procollagen III N-terminal Peptide (PIIINP)

Outcomes will be assessed at the start and every six weeks (at the end of each treatment period - allopurinol or placebo).

Overall study start date
22/06/2007

Completion date
01/09/2008

Eligibility

Key inclusion criteria
1. Documented Coronary artery Disease (CAD) on angiography
2. Chronic stable angina (greater than two months)
3. Able to do Exercise Treadmill Test (ETT)
4. Aged between 30 and 85 years

Participant type(s)
Patient

Age group
Adult

Sex
Not Specified

Target number of participants
60 patients

Key exclusion criteria
1. Contra-indication or unable to do ETT
2. Already on allopurinol or previous allergy to allopurinol
3. Left Ventricular (LV) ejection fraction less than 45%
4. Myocardial Infarction (MI) or Acute Coronary Syndrome (ACS) over the last two months

5. Change to anti-anginal therapy over the last month
6. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) within the last six months
7. Significant renal or hepatic impairment
8. On medication that may interact with allopurinol (e.g., warfarin)

Date of first enrolment
22/06/2007

Date of final enrolment
01/09/2008

Locations

Countries of recruitment
Scotland

United Kingdom

Study participating centre
Department of Clinical Pharmacology (Level 7)
Dundee
United Kingdom
DD1 9SY

Sponsor information

Organisation
University of Dundee (UK)

Sponsor details
11 Perth Road
Dundee
Scotland
United Kingdom
DD14HN

Sponsor type
University/education

Website
http://www.dundee.ac.uk/

ROR
https://ror.org/03h2bxq36

Funder(s)

Funder type
Charity

Funder Name
British Heart Foundation (UK)

Alternative Name(s)
the_bhf, The British Heart Foundation, BHF

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	19/06/2010		Yes	No